ethyl 2-amino-4-(((tert-butyldimethylsilyl)oxy)methyl)thiazole-5-carboxylate | 907545-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-amino-4-(((tert-butyldimethylsilyl)oxy)methyl)thiazole-5-carboxylate
• 英文别名: Ethyl 2-amino-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1,3-thiazole-5-carboxylate；ethyl 2-amino-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1,3-thiazole-5-carboxylate
• CAS: 907545-48-6
• 化学式: C₁₃H₂₄N₂O₃SSi
• 分子量: 316.497
• InChiKey: QUISMIBDDAHNRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.42
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 2-amino-4-(((tert-butyldimethylsilyl)oxy)methyl)thiazole-5-carboxylate 在 chromium(VI) oxide 、 盐酸 、 硫酸 、 t-butyl nitrite 、 copper dichloride 作用下， 以 1,4-二氧六环 、 水 、 丙酮 、 乙腈 为溶剂， 反应 5.0h， 生成 2-氯-5-(乙氧羰基)-1,3-噻唑-4-羧酸
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x
• 作为产物：
  描述：

  乙基2-氨基-4-(羟基甲基)-1,3-噻唑-5-羧酸酯 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以98%的产率得到ethyl 2-amino-4-(((tert-butyldimethylsilyl)oxy)methyl)thiazole-5-carboxylate
  参考文献：
  名称：

  [EN] NEW COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  该发明涉及用作NLRP3炎症小体产生抑制剂的新化合物，其中这些化合物由式(I)的化合物定义，并且整数R1、R2和R3如描述中定义，这些化合物可能用作药物，例如用于治疗与NLRP3炎症小体活性相关的疾病或紊乱。

  公开号：

  WO2022063896A1

文献信息

• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2022063896A1

  公开（公告）日：2022-03-31

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2and R3are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  该发明涉及用作NLRP3炎症小体产生抑制剂的新化合物，其中这些化合物由式(I)的化合物定义，并且整数R1、R2和R3如描述中定义，这些化合物可能用作药物，例如用于治疗与NLRP3炎症小体活性相关的疾病或紊乱。
• ANTIBACTERIAL PIPERDINE DERIVATIVES
  申请人：Basarab Gregory

  公开号：US20100179150A1

  公开（公告）日：2010-07-15

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化学式（I）的化合物及其药学上可接受的盐。描述了制备它们的过程，含有它们的药物组合物，它们作为药物的用途以及它们在治疗细菌感染中的用途。
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca, Intellectual Property

  公开号：US20130150366A1

  公开（公告）日：2013-06-13

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use in the treatment of bacterial infections are also described.

  本文描述了化学式(I)的化合物及其药学上可接受的盐。还描述了制备它们的过程、含有它们的制药组合物，以及它们在治疗细菌感染方面的用途。
• Antibacterial piperdine derivatives
  申请人：Basarab Gregory

  公开号：US08399489B2

  公开（公告）日：2013-03-19

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐。同时还描述了它们的制备过程、包含它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染方面的应用。
• IMIDAZOLE CARBONYL COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2226322B1

  公开（公告）日：2015-01-21